Genetic susceptibility to systemic sclerosis. From clinical aspect to genetic factor analyses

European Journal of Internal Medicine

Volumn 20, Issue 3, 2009, Pages 242-252

  Granel, Brigitte ^a,b   Bernard, Fanny ^a   Chevillard, Christophe ^a,c  

^a INSERM   (France)

^b HÔPITAL NORD   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Genetic association; Polymorphisms; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR2; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; FIBRILLIN 1; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ASPIRATION; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; CARDIOMYOPATHY; DISEASE CLASSIFICATION; DISEASE COURSE; FIBROSIS; GASTROINTESTINAL DISEASE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART LEFT VENTRICLE FAILURE; HEREDITY; HUMAN; IMMUNOREGULATION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LUNG CANCER; LUNG FIBROSIS; OBSTRUCTIVE AIRWAY DISEASE; PHENOTYPE; PLEURA DISEASE; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 64749091747     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.07.012     Document Type: Review

References (94)

1. Perera A., Fertig N., Lucas M., Rodriguez-Reyna T.S., Hu P., Steen V.D., et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 56 8 (2007) 2740-2746
2. Steen V.D. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 17 1 (1998) 48-54
3. Shand L., Lunt M., Nihtyanova S., Hoseini M., Silman A., Black C.M., et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 56 7 (2007) 2422-2431
4. Guiducci S., Giacomelli R., and Cerinic M.M. Vascular complications of scleroderma. Autoimmun Rev 6 8 (2007) 520-523
5. Cutolo M., Pizzorni C., Tuccio M., Burroni A., Craviotto C., Basso M., et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 43 6 (2004) 719-726
6. Allanore Y., Seror R., Chevrot A., Kahan A., and Drape J.L. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum 56 8 (2007) 2747-2754
7. Marie I. Gastrointestinal involvement in systemic sclerosis. Presse Med 35 12 Pt 2 (2006) 1952-1965
8. Highland K.B., Garin M.C., and Brown K.K. The spectrum of scleroderma lung disease. Semin Respir Crit Care Med 28 4 (2007) 418-429
9. Launay D., Mouthon L., Hachulla E., Pagnoux C., de Groote P., Remy-Jardin M., et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 34 5 (2007) 1005-1011
10. Launay D., Humbert M., and Hachulla E. Pulmonary arterial hypertension and systemic sclerosis. Presse Med 35 12 Pt 2 (2006) 1929-1937
11. van Laar J.M., Stolk J., and Tyndall A. Scleroderma lung: pathogenesis, evaluation and current therapy. Drugs 67 7 (2007) 985-996
12. Allanore Y., and Kahan A. Heart involvement in systemic sclerosis. Presse Med 35 12 Pt 2 (2006) 1938-1942
13. Steen V.D. Scleroderma renal crisis. Rheum Dis Clin North Am 29 2 (2003) 315-333
14. Penn H., Howie A.J., Kingdon E.J., Bunn C.C., Stratton R.J., Black C.M., et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. Qjm 100 8 (2007) 485-494
15. Teixeira L., Mouthon L., Mahr A., Berezné A., Agard C., Mehrenberger M., et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 67 1 (2008) 110-116
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23 5 (1980) 581-590
17. Johnson S.R., and Laxer R.M. Classification in systemic sclerosis. J Rheumatol 33 5 (2006) 840-841
18. Nadashkevich O., Davis P., and Fritzler M.J. Revising the classification criteria for systemic sclerosis. Arthritis Rheum 55 6 (2006) 992-993
19. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger Jr. T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15 2 (1988) 202-205
20. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich E., Goulet J.R., et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 81 2 (2002) 154-167
21. Wollheim F.A. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 44 10 (2005) 1212-1216
22. Granel B., Chevillard C., and Dessein A. [Genetic factors predisposing to fibrosis in systemic sclerosis]. Rev Med Interne 26 4 (2005) 294-303
23. Johnson R.W., Tew M.B., and Arnett F.C. The genetics of systemic sclerosis. Curr Rheumatol Rep 4 2 (2002) 99-107
24. Artlett C.M. Immunology of systemic sclerosis. Front Biosci 10 (2005) 1707-1719
25. Whiteside T.L., Medsger Jr. T.A., and Rodnan G.P. HLA-DR antigens in progressive systemic sclerosis (scleroderma). J Rheumatol 10 1 (1983) 128-131
26. Steen V.D., Ziegler G.L., Rodnan G.P., and Medsger Jr. T.A. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27 2 (1984) 125-131
27. Reveille J.D., Durban E., MacLeod-St Clair M.J., Goldstein R., Moreda R., Altman R.D., et al. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 90 3 (1992) 973-980
28. Feghali-Bostwick C., Medsger Jr. T.A., and Wright T.M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 48 7 (2003) 1956-1963
29. Zhou X., Tan F.K., Xiong M., Arnett F.C., and Feghali-Bostwick C.A. Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum 52 10 (2005) 3305-3314
30. Pablos J.L., Everett E.T., and Norris J.S. The tight skin mouse: an animal model of systemic sclerosis. Clin Exp Rheumatol 22 3 Suppl 33 (2004) S81-85
31. Jimenez S.A., and Christner P.J. Murine animal models of systemic sclerosis. Curr Opin Rheumatol 14 6 (2002) 671-680
32. Zhang Y., and Gilliam A.C. Animal models for scleroderma: an update. Curr Rheumatol Rep 4 2 (2002) 150-162
33. Jimenez S.A., and Derk C.T. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140 1 (2004) 37-50
34. Abraham D.J., and Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26 11 (2005) 587-595
35. Assassi S., and Tan F.K. Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays. Curr Opin Rheumatol 17 6 (2005) 761-767
36. Allanore Y., Wipff J., Kahan A., and Boileau C. Genetic basis for systemic sclerosis. Joint Bone Spine 74 6 (2007) 577-583
37. Kawaguchi Y., McCarthy S.A., Watkins S.C., and Wright T.M. Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 31 10 (2004) 1946-1954
38. Kawaguchi Y., Hara M., Kamatani N., and Wright T.M. Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1 alpha in systemic sclerosis. Arthritis Rheum 48 1 (2003) 193-202
39. Mattuzzi S., Barbi S., Carletto A., Ravagnani V., Moore P.S., Bambara L.M., et al. Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol 34 5 (2007) 997-1004
40. Hutyrova B., Lukac J., Bosak V., Buc M., du Bois R., and Petrek M. Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis. J Rheumatol 31 1 (2004) 81-84
41. Beretta L., Cappiello F., Moore J.H., and Scorza R. Interleukin-1 gene complex single nucleotide polymorphisms in systemic sclerosis: a further step ahead. Hum Immunol 69 3 (2008) 187-192
42. Reitamo S., Remitz A., Tamai K., and Uitto J. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest 94 6 (1994) 2489-2492
43. Yamamoto T., Eckes B., and Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 281 1 (2001) 200-205
44. Hudson L.L., Rocca K.M., Kuwana M., and Pandey J.P. Interleukin-10 genotypes are associated with systemic sclerosis and influence disease-associated autoimmune responses. Genes Immun 6 3 (2005) 274-278
45. Crilly A., Hamilton J., Clark C.J., Jardine A., and Madhok R. Analysis of the 5¢ flanking region of the interleukin 10 gene in patients with systemic sclerosis. Rheumatology (Oxford) 42 11 (2003) 1295-1298
46. Granel B., Chevillard C., and Dessein A. Interleukin 13 and interleukin 13 receptor involvement in systemic sclerosis. Rev Med Interne 28 9 (2007) 613-622
47. Granel B., Chevillard C., Allanore Y., Arnaud V., Cabantous S., Marquet S., et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics 58 8 (2006) 693-699
48. Granel B., Allanore Y., Chevillard C., Arnaud V., Marquet S., Weiller P.J., et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol 33 10 (2006) 2015-2019
49. Yamane K., Ihn H., Asano Y., Jinnin M., and Tamaki K. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol 171 7 (2003) 3855-3862
50. Sato H., Lagan A.L., Alexopoulou C., Vassilakis D.A., Ahmad T., Pantelidis P., et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 50 2 (2004) 558-564
51. Tolusso B., Fabris M., Caporali R., Cuomo G., Isola M., Soldano F., et al. - 238 and + 489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. Immunol Lett 96 1 (2005) 103-108
52. Takeuchi F., Nabeta H., Fussel M., Conrad K., and Frank K.H. Association of the TNFa13 microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis 59 4 (2000) 293-296
53. Pandey J.P., and Takeuchi F. TNF-alpha and TNF-beta gene polymorphisms in systemic sclerosis. Hum Immunol 60 11 (1999) 1128-1130
54. Leask A., and Abraham D.J. TGF-beta signaling and the fibrotic response. Faseb J 18 7 (2004) 816-827
55. Querfeld C., Eckes B., Huerkamp C., Krieg T., and Sollberg S. Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci 21 1 (1999) 13-22
56. Crilly A., Hamilton J., Clark C.J., Jardine A., and Madhok R. Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 61 8 (2002) 678-681
57. Sugiura Y., Banno S., Matsumoto Y., Niimi T., Yoshinouchi T., Hayami Y., et al. Transforming growth factor beta1 gene polymorphism in patients with systemic sclerosis. J Rheumatol 30 7 (2003) 1520-1523
58. Zhou X., Tan F.K., Stivers D.N., and Arnett F.C. Microsatellites and intragenic polymorphisms of transforming growth factor beta and platelet-derived growth factor and their receptor genes in Native Americans with systemic sclerosis (scleroderma): a preliminary analysis showing no genetic association. Arthritis Rheum 43 5 (2000) 1068-1073
59. Pandey J.P., and LeRoy E.C. A profibrotic polymorphism (of TGFbeta1) in systemic sclerosis. Ann Rheum Dis 61 8 (2002) 671-672
60. Susol E., Rands A.L., Herrick A., McHugh N., Barrett J.H., Ollier W.E., et al. Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis. Rheumatology (Oxford) 39 12 (2000) 1332-1336
61. Leask A. Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Keio J Med 53 2 (2004) 74-77
62. Takehara K. Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol 30 4 (2003) 755-759
63. Fonseca C., Lindahl G.E., Ponticos M., Sestini P., Renzoni E.A., Holmes A.M., et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 357 12 (2007) 1210-1220
64. Gourh P., Mayes M.D., and Arnett F.C. CTGF polymorphism associated with systemic sclerosis. N Engl J Med 358 3 (2008) 308-309 author reply 9
65. Gharaee-Kermani M., Denholm E.M., and Phan S.H. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 271 30 (1996) 17779-17784
66. Atamas S.P., and White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 15 6 (2003) 772-777
67. Distler O., Pap T., Kowal-Bielecka O., Meyringer R., Guiducci S., Landthaler M., et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 44 11 (2001) 2665-2678
68. Karrer S., Bosserhoff A.K., Weiderer P., Distler O., Landthaler M., Szeimies R.M., et al. The - 2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 124 1 (2005) 92-98
69. Renzoni E., Lympany P., Sestini P., Pantelidis P., Wells A., Black C., et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 43 7 (2000) 1633-1640
70. Allanore Y., Borderie D., Lemarechal H., Ekindjian O.G., and Kahan A. Lack of association of eNOS (G894T) and p22phox NADPH oxidase subunit (C242T) polymorphisms with systemic sclerosis in a cohort of French Caucasian patients. Clin Chim Acta 350 1-2 (2004) 51-55
71. Allanore Y., Borderie D., Airo P., Guiducci S., Czirják L., Nasonov E.L., et al. Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis 66 2 (2007) 257-259
72. Pushpakom S.P., Herrick A.L., Kumar S., and Worthington J. Polymorphisms in COL15 gene are not associated with systemic sclerosis. J Rheumatol 35 2 (2008) 251-253
73. Morse J., Barst R., Horn E., Cuervo N., Deng Z., and Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 29 11 (2002) 2379-2381
74. Tabor H.K., Risch N.J., and Myers R.M. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 3 5 (2002) 391-397
75. Fonseca C., and Denton C.P. Genetic association studies in systemic sclerosis: more evidence of a complex disease. J Rheumatol 34 5 (2007) 903-905
76. Zhou X., Tan F.K., Wang N., Xiong M., Maghidman S., Reveille J.D., et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 48 9 (2003) 2585-2592
77. Zhou X., Tan F.K., Reveille J.D., Wallis D., Milewicz D.M., Ahn C., et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum 46 11 (2002) 2990-2999
78. Lagan A.L., Pantelidis P., Renzoni E.A., Fonseca C., Beirne P., Taegtmeyer A.B., et al. Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. Rheumatology (Oxford) 44 2 (2005) 197-201
79. Hata R., Akai J., Kimura A., Ishikawa O., Kuwana M., and Shinkai H. Association of functional microsatellites in the human type I collagen alpha2 chain (COL1A2) gene with systemic sclerosis. Biochem Biophys Res Commun 272 1 (2000) 36-40
80. Tan F.K., Stivers D.N., Foster M.W., Chakraborty R., Howard R.F., Milewicz D.M., et al. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 41 10 (1998) 1729-1737
81. Tan F.K., Wang N., Kuwana M., Chakraborty R., Bona C.A., Milewicz D.M., et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 44 4 (2001) 893-901
82. Wipff J., Giraud M., Sibilia J., Mouthon L., Meyer O., Tiev K., et al. Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol 35 4 (2008) 643-649 (Apr)
83. Avila J.J., Lympany P.A., Pantelidis P., Welsh K.I., Black C.M., and du Bois R.M. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 20 1 (1999) 106-112
84. Fonseca C., Renzoni E., Sestini P., Pantelidis P., Lagan A., Bunn C., et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum 54 9 (2006) 3034-3042
85. Wipff J., Kahan A., Hachulla E., Sibilia J., Cabane J., Meyer O., et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 46 4 (2007) 622-625
86. Fatini C., Gensini F., Sticchi E., Battaglini B., Angotti C., Conforti M.L., et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med 112 7 (2002) 540-544
87. Assassi S., Mayes M.D., McNearney T., Fischbach M., Reveille J.D., Arnett F.C., et al. Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis. Am J Med 118 8 (2005) 907-911
88. Hudson L.L., Silver R.M., and Pandey J.P. Ethnic differences in cytotoxic T lymphocyte associated antigen 4 genotype associations with systemic sclerosis. J Rheumatol 31 1 (2004) 85-87
89. Almasi S., Erfani N., Mojtahedi Z., Rajaee A., and Ghaderi A. Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population. Genes Immun 7 5 (2006) 401-406
90. Takeuchi F., Kawasugi K., Nabeta H., Mori M., and Tanimoto K. Association of CTLA-4 with systemic sclerosis in Japanese patients. Clin Exp Rheumatol 20 6 (2002) 823-828
91. Takeuchi F., Nakaue N., Kawasugi K., Mori M., Kuwata S., and Tanimoto K. The CTLA-4 - 1661A/G and - 1772T/C dimorphisms in Japanese patients with systemic sclerosis. Rheumatol Int 27 8 (2007) 785-787
92. Tsuchiya N., Kuroki K., Fujimoto M., Murakami Y., Tedder T.F., Tokunaga K., et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 50 12 (2004) 4002-4007
93. Gourh P., Tan F.K., Assassi S., Ahn C.W., McNearney T.A., Fischbach M., et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 54 12 (2006) 3945-3953
94. *620W allele and systemic sclerosis in the French Caucasian population. Ann Rheum Dis 65 9 (2006) 1230-1232